PE20050896A1 - Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos - Google Patents

Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos

Info

Publication number
PE20050896A1
PE20050896A1 PE2005000069A PE2005000069A PE20050896A1 PE 20050896 A1 PE20050896 A1 PE 20050896A1 PE 2005000069 A PE2005000069 A PE 2005000069A PE 2005000069 A PE2005000069 A PE 2005000069A PE 20050896 A1 PE20050896 A1 PE 20050896A1
Authority
PE
Peru
Prior art keywords
tirosine
intermediaries
receptors
quinoline
kinases
Prior art date
Application number
PE2005000069A
Other languages
English (en)
Inventor
Youchu Wang
Chew Warren
Maria Papamichelakis
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20050896A1 publication Critical patent/PE20050896A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A METODOS DE PREPARACION DE COMPUESTOS DE QUINOLINA 4-SUSTITUIDA DE FORMULA I DONDE LG" ES MORFOLINO, O-MESILO, O-TOSILO, ENTRE OTROS; PG ES ACILO, BENZAMIDA, CH3OC(O)-, ENTRE OTROS; A ES O, NH, S, ENTRE OTROS; G, R1 Y R4 SON CADA UNO H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS. ES COMPUESTO PREFERIDO: 6-ACETAMIDA-4-CLORO-3-CIANO-7-ETOXIQUINOLINA. DICHOS COMPUESTOS SON INTERMEDIARIOS EN LA ELABORACION DE INHIBIDORES DE TIROSINA QUINASAS DE RECEPTORES
PE2005000069A 2004-01-16 2005-01-17 Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos PE20050896A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53732904P 2004-01-16 2004-01-16

Publications (1)

Publication Number Publication Date
PE20050896A1 true PE20050896A1 (es) 2005-11-14

Family

ID=34807094

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000069A PE20050896A1 (es) 2004-01-16 2005-01-17 Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos

Country Status (20)

Country Link
US (2) US7432377B2 (es)
EP (1) EP1711467A2 (es)
KR (1) KR20060123545A (es)
CN (1) CN1930128A (es)
AR (1) AR047424A1 (es)
AU (1) AU2005206541A1 (es)
BR (1) BRPI0520812A2 (es)
CA (1) CA2553729A1 (es)
CR (1) CR8530A (es)
EC (1) ECSP066773A (es)
GT (1) GT200500008A (es)
MY (1) MY136959A (es)
NO (1) NO20063501L (es)
PA (1) PA8621501A1 (es)
PE (1) PE20050896A1 (es)
RU (1) RU2006127414A (es)
SG (1) SG149817A1 (es)
TW (1) TW200526219A (es)
UA (1) UA85698C2 (es)
WO (1) WO2005070890A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711467A2 (en) * 2004-01-16 2006-10-18 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
CN101180273A (zh) * 2005-05-25 2008-05-14 惠氏公司 合成6-烷基氨基喹啉衍生物的方法
EP1883621A2 (en) * 2005-05-25 2008-02-06 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
CN101203494A (zh) * 2005-05-25 2008-06-18 惠氏公司 合成经取代3-氰基喹啉和其中间物的方法
TW200808728A (en) * 2006-05-23 2008-02-16 Wyeth Corp Method of preparing 4-halogenated quinoline intermediates
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8063220B2 (en) 2007-06-22 2011-11-22 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
MX2010012703A (es) 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010056311A1 (en) 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
CN103096716B (zh) 2010-08-10 2016-03-02 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
CN104284584B (zh) 2012-03-15 2019-06-04 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的盐
SG11201405691WA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Solid forms of an epidermal growth factor receptor kinase inhibitor
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
PL3188642T3 (pl) * 2014-09-01 2018-10-31 Electrolux Appliances AB Zespół wspornikowy
EP3359526A4 (en) 2015-10-05 2019-04-03 The Trustees of Columbia University in the City of New York ACTIVATORS OF AUTOPHAGIC FLOW AND PHOSPHOLIPASE D AND CLAIRANCE OF PROTEIN AGGREGATES COMPRISING TAU AND TREATMENT OF PROTEINEOPATHIES
CN105503720B (zh) * 2015-12-31 2018-07-03 重庆威鹏药业有限公司 来那替尼中间体的制备方法
CN107417612A (zh) * 2017-07-25 2017-12-01 广州大学 一种喹啉衍生物的合成方法
CN107501174A (zh) * 2017-07-25 2017-12-22 广州大学 一种喹啉衍生物的合成方法
CN107501175A (zh) * 2017-07-25 2017-12-22 广州大学 一种喹啉衍生物的合成方法
RS65621B1 (sr) 2018-04-18 2024-07-31 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, sastavi i njihova upotreba
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
IL133009A0 (en) 1997-05-28 2001-03-19 Aventis Pharm Prod Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
JP4537582B2 (ja) 1998-09-29 2010-09-01 アメリカン・サイアナミド・カンパニー プロテインチロシンキナーゼインヒビターとしての置換３−シアノキノリン
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
JP2003520855A (ja) 2000-01-28 2003-07-08 アストラゼネカ アクチボラグ 化学的化合物
WO2002036570A1 (en) * 2000-11-02 2002-05-10 Astrazeneca Ab 4-substituted quinolines as antitumor agents
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
JP2005536462A (ja) * 2002-04-30 2005-12-02 ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド カスパーゼ−３阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
US7365203B2 (en) * 2003-09-15 2008-04-29 Wyeth Process for the synthesis of 6-amino-4-(3-chloro-4-fluoro-phenylamino)-7-ethoxy-quinoline-3-carbonitrile
EP1711467A2 (en) 2004-01-16 2006-10-18 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity

Also Published As

Publication number Publication date
WO2005070890A3 (en) 2005-11-03
UA85698C2 (ru) 2009-02-25
US7432377B2 (en) 2008-10-07
CA2553729A1 (en) 2005-08-04
AR047424A1 (es) 2006-01-18
CN1930128A (zh) 2007-03-14
RU2006127414A (ru) 2008-02-27
BRPI0520812A2 (pt) 2009-10-06
US20090030197A1 (en) 2009-01-29
US20050159446A1 (en) 2005-07-21
CR8530A (es) 2008-09-23
TW200526219A (en) 2005-08-16
GT200500008A (es) 2005-08-16
NO20063501L (no) 2006-09-28
PA8621501A1 (es) 2005-08-10
KR20060123545A (ko) 2006-12-01
MY136959A (en) 2008-12-31
ECSP066773A (es) 2006-11-16
AU2005206541A1 (en) 2005-08-04
WO2005070890A2 (en) 2005-08-04
EP1711467A2 (en) 2006-10-18
SG149817A1 (en) 2009-02-27

Similar Documents

Publication Publication Date Title
PE20050896A1 (es) Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos
AR055878A1 (es) Derivados de ciclopropanocarboxamida
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
AR052312A1 (es) 2- anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y medicamentos preparados en base al compuesto
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
EA200900934A1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
NO20060154L (no) Imidazolyl-derivater
EA200700441A1 (ru) НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
NO20065184L (no) 1-amino-ftalazinderivater, deres fremstilling og terapeutiske anvendelse derav
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
UY29015A1 (es) Derivados de pirido-pirimidina, su preparacinn, su aplicacinn en terapeutica
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
CY1112449T1 (el) Υποκατεστημενα ν-βενζο [d] ισοξαζολ-3-υλ-αμινο παραγωγα ως αναστολεις υποδοχεων mglur5, σεροτονινης-(5-ητ) και νοραδρεναλινης και η χρηση αυτων για την παραγωγη φαρμακων
AR041689A1 (es) Derivados de piridoindolona substituidos en 3- por un fenilo su preparacion y su aplicacion en terapeutica
NO20074622L (no) Metabolitter for NK-1 antagonister for brekninger
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed